Dynavax Technologies (NASDAQ:DVAX) Cut to “Hold” at William Blair

William Blair lowered shares of Dynavax Technologies (NASDAQ:DVAX) from an outperform rating to a hold rating in a research note issued to investors on Wednesday morning, MarketBeat.com reports.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $15.38 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The company has a market capitalization of $1.81 billion, a PE ratio of -41.57 and a beta of 0.89. The company has a 50 day moving average price of $11.10 and a 200-day moving average price of $10.58. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $15.49.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.07. The company had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. As a group, equities analysts forecast that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Blair William & Co. IL increased its holdings in shares of Dynavax Technologies by 0.3% in the 2nd quarter. Blair William & Co. IL now owns 2,279,647 shares of the biopharmaceutical company’s stock valued at $22,614,000 after acquiring an additional 6,940 shares during the period. Marshall Wace LLP boosted its position in Dynavax Technologies by 12.2% during the third quarter. Marshall Wace LLP now owns 2,036,003 shares of the biopharmaceutical company’s stock valued at $20,218,000 after purchasing an additional 221,069 shares in the last quarter. Bank of America Corp DE boosted its position in Dynavax Technologies by 25.7% during the third quarter. Bank of America Corp DE now owns 1,458,087 shares of the biopharmaceutical company’s stock valued at $14,479,000 after purchasing an additional 298,106 shares in the last quarter. Glenmede Investment Management LP grew its stake in Dynavax Technologies by 23.8% in the third quarter. Glenmede Investment Management LP now owns 1,264,369 shares of the biopharmaceutical company’s stock valued at $12,555,000 after purchasing an additional 243,240 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in Dynavax Technologies by 48.4% in the first quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock worth $15,289,000 after purchasing an additional 384,288 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.